

# Zilucoplan for Severe gMG Exacerbations

NCT07215949

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Miriam Freimer
Enrollment	15 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Patient determined to have severe MG exacerbation (e.g. bulbar and/or respiratory symptoms requiring hospitalization, neck extension weakness)
  - MGFA class II - IVb
  - Male or female aged e18
  - MG-ADL e6 in non-ocular domains
  - Serology - AChR antibody positive (or historically available data)
- ... and 3 more (see full listing online)

### Exclusion (10)

- History of meningococcal disease
  - Participants requiring intubation prior to study start.
  - Recent significant infections which could have caused exacerbation e.g. sepsis and wound infections
  - Pregnancy or lactating
  - Recent surgery (<4 weeks). Minor procedures/surgeries allowed at the discretion of the site principal investigator
- ... and 5 more (see full listing online)

## Locations (1 total)

---

The Ohio State University, Columbus, Ohio, United States